20830-75-5

20830-75-5结构式
20830-75-5结构式

化源商城直购

中文名 地高辛
英文名 digoxin
中文别名 异羟基洋地黄毒苷
英文别名 Dixina
Digacin
Digonix
Cordioxil
Homolle's digitalin
Mapluxin
Lanocardin
card-20(22)-enolide, 3-[[O-2,6-dideoxy-b-D-ribo-hexopyranosyl-(1®4)-O-2,6-dideoxy-b-D-ribo-hexopyranosyl-(1®4)-2,6-dideoxy-b-D-ribo-hexopyranosyl]oxy]-12,14-dihydroxy-, (3b,5b,12b)-
Lanacrist
4-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-3-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-Dihydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-4-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-4-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-12,14-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2(5H)-furanon
Purgoxin
Longdigox
EINECS 244-068-1
Digoxina-Sandoz
ROUGOXIN
Stillacor
NeoDioxanin
SK-Digoxin
Natigoxin
Davoxin
Digoxin Nativelle
Fargoxin
4-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-3-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-Dihydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-4-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-4-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-12,14-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]furan-2(5H)-on
Digos
Dimecip
Neo-Lanicor
digoxin
12b-Hydroxydigitoxin
Digon
(3b,5b,12b)-3-{[2,6-dideoxy-b-D-ribo-hexopyranosyl-(1®4)-2,6-dideoxy-b-D-ribo-hexopyranosyl-(1®4)-2,6-dideoxy-b-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide
card-20(22)-enolide, 3-[[O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-β-D-ribo-hexopyranosyl]oxy]-12,14-dihydroxy-, (3β,5β,12β)
Lanacordin
Dynamos
Saroxin
Coragoxine
Dokim
Lenoxin
4-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-3-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-4-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-4-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-12,14-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]furan-2(5H)-one
LOE 908 hydrochloride
Grexin
Digoxin-Zori
4-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-3-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-Dihydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-4-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-4-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-12,14-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2(5H)-furanone
Cardiogoxin
Digossina
Cardigox
Hemigoxine Nativelle
(3β,5β,12β)-3-{[2,6-Dideoxy-β-D-ribo-hexopyranosyl-(1->;4)-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-β-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolid
4-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-3-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-Dihydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-4-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-4-hydroxy
(3β,5β,12β)-3-{[2,6-Didésoxy-β-D-ribo-hexopyranosyl-(1->4)-2,6-didésoxy-β-D-ribo-hexopyranosyl-(1->4)-2,6-didésoxy-β-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-ènolide
MFCD00003674
Lanatilin
Digomal
Digosin
Lanoxin PG
Lanikor
Lanorale
Lanoxicaps
Toloxin
Lanoxin
(3b,5b,12b)-3-[(O-2,6-Dideoxy-b-D-ribo-hexopyranosyl-(1®4)-O-2,6-dideoxy-b-D-ribo-hexopyranosyl-(1®4)-2,6-dideoxy-b-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxycard-20(22)-enolide
Cardioxin
card-20(22)-enolide, 3-[[O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-β-D-ribo-hexopyranosyl]oxy]-12,14-dihydroxy-, (3β,5β,12β)-
Lanicor
Card-20(22)-enolide, 3-[[O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-β-D-ribo-hexopyranosyl]oxy]-12,14-dihydroxy-, (3β,5β,12β)
 -
Novodigal-Amp.
Dilanacin
Vanoxin
[2H]-Digoxin
Lenoxicaps
Lifusin
(3β,5β,12β)-3-{[2,6-Dideoxy-β-D-ribo-hexopyranosyl-(1->;4)-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-β-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide
Eudigox
[14C]-Digoxin
描述 Digoxin是 Na+/K+-ATPase 的有效抑制剂,临床上用于治疗心律失常和心力衰竭。
相关类别
靶点

Na+/K+ ATPase[1]

体外研究 地高辛是一种钠钾ATP酶抑制剂,其Z值评分为-26.67,表明CHIKV感染中钠-钾ATP酶的功能。相对于DMSO处理的细胞,用地高辛处理U-2 OS细胞导致CHIKV感染的剂量依赖性降低,半最大有效浓度(EC 50)为48.8nM。地高辛处理类似地降低原代人滑膜成纤维细胞(HSF)和Vero非洲绿猴肾细胞的CHIKV感染,EC50分别为43.9nM和67.3nM。地高辛处理显着减少这些细胞类型中的CHIKV感染,ST2细胞中EC50为16.2μM,C2C12细胞中为23.2μM,是U-2OS细胞中地高辛EC50的330和475倍。在使用1μM地高辛治疗后24小时,细胞活力仅受到适度损害,地高辛的剂量是地高辛EC50的20倍,用于CHIKV在这些细胞中的抗病毒活性[1]。
细胞实验 将接种在60mm直径培养皿中的U-2 OS细胞与DMSO,10μMSTS作为细胞凋亡诱导剂或在37℃下增加浓度的地高辛培养6小时。用荧光激活细胞分选仪(FACS)缓冲液(含2%FBS的PBS)洗涤细胞并用PI染色。使用BD LSRII流式细胞仪和FlowJo软件定量细胞染色。或者,将接种在96孔板中的U-2 OS细胞与DMSO,STS或递增浓度的地高辛在37℃温育6或24小时。将PrestoBlue试剂加入到化合物处理的细胞的上清液中,并将细胞在37℃下孵育30分钟。使用Synergy H1平板读数器[1]量化荧光作为细胞活力的替代指标。
参考文献

[1]. Ashbrook AW, et al. Antagonism of the Sodium-Potassium ATPase Impairs Chikungunya Virus Infection. MBio. 2016 May 24;7(3). pii: e00693-16.

密度 1.4±0.1 g/cm3
沸点 931.6±65.0 °C at 760 mmHg
熔点 248-250ºC
分子式 C41H64O14
分子量 780.938
闪点 278.5±27.8 °C
精确质量 780.429626
PSA 203.06000
LogP 0.85
外观性状 透明至哑色,无色至淡黄色液体
蒸汽压 0.0±0.6 mmHg at 25°C
折射率 1.602
储存条件

保持贮藏器密封

放入紧密的贮藏器内,储存在阴凉,干燥的地方
稳定性

如果遵照规格使用和储存则不会分解

避免接触氧化物
水溶解性 水溶性:不溶;水溶解度:64.8 mg/l   25 °C;不溶:氯仿,乙醚,丙酮
分子结构

1、 摩尔折射率:196.38

2、 摩尔体积(m3/mol):572.3

3、 等张比容(90.2K):1622.4

4、 表面张力(dyne/cm):64.5

5、 极化率(10-24cm3):77.85

计算化学

1、疏水参数计算参考值(XlogP):1.3

2、氢键供体数量:6

3、氢键受体数量:14

4、可旋转化学键数量:7

5、互变异构体数量:

6、拓扑分子极性表面积(TPSA):203

7、重原子数量:55

8、表面电荷:0

9、复杂度:1450

10、同位素原子数量:0

11、确定原子立构中心数量:21

12、不确定原子立构中心数量:0

13、确定化学键立构中心数量:0

14、不确定化学键立构中心数量:0

15、共价键单元数量:1

更多

1.性状:白色粉末

2.密度(g/mL,25/4℃):未确定

3.相对蒸汽密度(g/mL,空气=1):未确定

4.熔点(ºC):248

5.沸点(ºC,常压):未确定

6.沸点(ºC,5.2kPa):未确定

7.折射率:12°(C=10,Pyridine)

8.闪点(ºC):未确定

9.比旋光度(º):未确定

10.自燃点或引燃温度(ºC):未确定

11.蒸气压(kPa,25ºC):未确定

12.饱和蒸气压(kPa,60ºC):未确定

13.燃烧热(KJ/mol):未确定

14.临界温度(ºC):未确定

15.临界压力(KPa):未确定

16.油水(辛醇/水)分配系数的对数值:未确定

17.爆炸上限(%,V/V):未确定

18.爆炸下限(%,V/V):未确定

19.溶解性:未确定

: Digoxin
产品名称
: Cerilliant
1.2 鉴别的其他方法
无数据资料
1.3 有关的确定了的物质或混合物的用途和建议不适合的用途
仅用于研发。不作为药品、家庭或其它用途。

模块2. 危险性概述
2.1 GHS-分类
易燃液体 (类别 2)
急性毒性, 经口 (类别 3)
急性毒性, 吸入 (类别 3)
急性毒性, 经皮 (类别 3)
特异性靶器官系统毒性(一次接触) (类别 1)
2.2 GHS 标记要素,包括预防性的陈述
象形图
警示词危险
危险申明
H225高度易燃液体和蒸气
H301吞咽会中毒
H311皮肤接触会中毒
H331吸入会中毒。
H370对器官造成损害。
警告申明
预防
P210远离热源、火花、明火和热表面。- 禁止吸烟。
P233保持容器密闭。
P240容器和接收设备接地/等势连接。
P241使用防爆的电气/ 通风/ 照明 设备。
P242只能使用不产生火花的工具。
P243采取防止静电放电的措施。
P260不要吸入粉尘/ 烟/ 气体/ 烟雾/ 蒸汽/ 喷雾。
P264操作后彻底清洁皮肤。
P270使用本产品时不要进食、饮水或吸烟。
P271只能在室外或通风良好之处使用。
P280戴防护手套/穿防护服/戴护目镜/戴面罩.
响应
P301 + P310如果吞下去了: 立即呼救解毒中心或医生。
P303 + P361 + P353如皮肤(或头发)沾染:立即去除/ 脱掉所有沾染的衣服。用水清洗皮肤/
淋浴。
P304 + P340如吸入: 将患者移到新鲜空气处休息,并保持呼吸舒畅的姿势。
P307 + P311如接触到:呼叫解毒中心或医生。
P322具体措施(见本标签上提供的急救指导)。
P330漱口。
P361立即去除/脱掉所有沾染的衣服。
P363沾染的衣服清洗后方可重新使用。
P370 + P378火灾时: 用干的砂子,干的化学品或耐醇性的泡沫来灭火。
储存
P403 + P233存放于通风良的地方。 保持容器密闭。
P403 + P235存放在通风良好的地方。保持低温。
P405存放处须加锁。
处置
P501将内容物/ 容器处理到得到批准的废物处理厂。
2.3 其它危害物 - 无

模块3. 成分/组成信息
3.2 混合物
组分分类浓度或浓度范围
Methanol
化学文摘登记号(CA67-56-1Flam. Liq. 2; Acute Tox. 3;50 - 100 %
S No.)200-659-6STOT SE 1; H225, H301,
EC-编号603-001-00-XH311, H331, H370
索引编号01-2119433307-44-XXXX
注册号
如需在本章节中提及的H类告知和R类描述的全部文字说明,请见第16章节.

模块4. 急救措施
4.1 必要的急救措施描述
一般的建议
请教医生。 向到现场的医生出示此安全技术说明书。
吸入
如果吸入,请将患者移到新鲜空气处。 如呼吸停止,进行人工呼吸。 请教医生。
皮肤接触
用肥皂和大量的水冲洗。 立即将患者送往医院。 请教医生。
眼睛接触
用水冲洗眼睛作为预防措施。
食入
禁止催吐。 切勿给失去知觉者通过口喂任何东西。 用水漱口。 请教医生。
4.2 主要症状和影响,急性和迟发效应
据我们所知,此化学,物理和毒性性质尚未经完整的研究。
如吞服甲醇可能致命或致盲。, 不能制成无毒性的。, 摄入的影响可包括:, 恶心, 头痛, 呕吐, 消化系统失调,
头晕, 虚弱, 混乱
4.3 及时的医疗处理和所需的特殊处理的说明和指示
无数据资料

模块5. 消防措施
5.1 灭火介质
灭火方法及灭火剂
用水雾,抗乙醇泡沫,干粉或二氧化碳灭火。
5.2 源于此物质或混合物的特别的危害
无数据资料
5.3 给消防员的建议
如必要的话,戴自给式呼吸器去救火。
5.4 进一步信息
用水喷雾冷却未打开的容器。

模块6. 泄露应急处理
6.1 作业人员防护措施、防护装备和应急处置程序
戴呼吸罩。 避免吸入蒸气、烟雾或气体。 保证充分的通风。 移去所有火源。 人员疏散到安全区域。
谨防蒸气积累达到可爆炸的浓度。蒸气能在低洼处积聚。
6.2 环境保护措施
如能确保安全,可采取措施防止进一步的泄漏或溢出。 不要让产品进入下水道。
6.3 泄漏化学品的收容、清除方法及所使用的处置材料
围堵溢出,用防电真空清洁器或湿刷子将溢出物收集起来,并放置到容器中去,根据当地规定处理(见第13部
分)。
6.4 参考其他部分
丢弃处理请参阅第13节。

模块7. 操作处置与储存
7.1 安全操作的注意事项
避免接触皮肤和眼睛。 避免吸入蒸气和烟雾。
切勿靠近火源。-严禁烟火。采取措施防止静电积聚。
7.2 安全储存的条件,包括任何不兼容性
贮存在阴凉处。 使容器保持密闭,储存在干燥通风处。
打开了的容器必须仔细重新封口并保持竖放位置以防止泄漏。
建议的贮存温度: -20 °C
7.3 特定用途
无数据资料

模块8. 接触控制和个体防护
8.1 容许浓度
最高容许浓度
组分化学文摘登值容许浓度基准
记号(CAS
No.)
Methanol67-56-1PC-25 mg/m3工作场所有害因素职业接触限值 -
TWA化学有害因素
备注皮
PC-50 mg/m3工作场所有害因素职业接触限值 -
STEL化学有害因素

8.2 暴露控制
适当的技术控制
避免与皮肤、眼睛和衣服接触。 休息前和操作本品后立即洗手。
个体防护设备
眼/面保护
面罩與安全眼鏡请使用经官方标准如NIOSH (美国) 或 EN 166(欧盟) 检测与批准的设备防护眼部。
皮肤保护
戴手套取 手套在使用前必须受检查。
请使用合适的方法脱除手套(不要接触手套外部表面),避免任何皮肤部位接触此产品.
使用后请将被污染过的手套根据相关法律法规和有效的实验室规章程序谨慎处理. 请清洗并吹干双手
所选择的保护手套必须符合EU的89/686/EEC规定和从它衍生出来的EN 376标准。
身体保护
全套防化学试剂工作服, 阻燃防静电防护服,
防护设备的类型必须根据特定工作场所中的危险物的浓度和数量来选择。
呼吸系统防护
如危险性评测显示需要使用空气净化的防毒面具,请使用全面罩式多功能防毒面具(US)或ABEK型
(EN
14387)防毒面具筒作为工程控制的候补。如果防毒面具是保护的唯一方式,则使用全面罩式送风防
毒面具。 呼吸器使用经过测试并通过政府标准如NIOSH(US)或CEN(EU)的呼吸器和零件。

模块9. 理化特性
9.1 基本的理化特性的信息
a) 外观与性状
形状: 液体
b) 气味
无数据资料
c) 气味阈值
无数据资料
d) pH值
无数据资料
e) 熔点/凝固点
无数据资料
f) 沸点、初沸点和沸程
64 - 65 °C 在 1.013 hPa
g) 闪点
9.7 °C - 闭杯
h) 蒸发速率
无数据资料
i) 易燃性(固体,气体)
无数据资料
j) 高的/低的燃烧性或爆炸性限度 爆炸上限: 36 %(V)
爆炸下限: 6 %(V)
k) 蒸气压
无数据资料
l) 蒸汽密度
无数据资料
m) 密度/相对密度
0.791 g/cm3 在 20 °C
n) 水溶性
无数据资料
o) n-辛醇/水分配系数
无数据资料
p) 自燃温度
无数据资料
q) 分解温度
无数据资料
r) 粘度
无数据资料

模块10. 稳定性和反应活性
10.1 反应性
无数据资料
10.2 稳定性
无数据资料
10.3 危险反应
无数据资料
10.4 应避免的条件
热,火焰和火花。 极端温度和直接日晒。
10.5 不相容的物质
酸, 氧化剂, 碱金属, 强氧化剂, 强酸, 酰基氯, 酸酐, 还原剂, 强还原剂, 含磷卤化物
10.6 危险的分解产物
其它分解产物 - 无数据资料

模块11. 毒理学资料
11.1 毒理学影响的信息
急性毒性
无数据资料
皮肤刺激或腐蚀
无数据资料
眼睛刺激或腐蚀
无数据资料
呼吸道或皮肤过敏
无数据资料
生殖细胞突变性
无数据资料
致癌性
IARC:
此产品中没有大于或等于 0。1%含量的组分被 IARC鉴别为可能的或肯定的人类致癌物。
生殖毒性
无数据资料
特异性靶器官系统毒性(一次接触)
无数据资料
特异性靶器官系统毒性(反复接触)
无数据资料
吸入危险
无数据资料
潜在的健康影响
吸入吸入会中毒。 可能引起呼吸道刺激。
摄入误吞会中毒。
皮肤如果被皮肤吸收会有毒性 可能引起皮肤刺激。
眼睛可能引起眼睛刺激。
接触后的征兆和症状
据我们所知,此化学,物理和毒性性质尚未经完整的研究。
如吞服甲醇可能致命或致盲。, 不能制成无毒性的。, 摄入的影响可包括:, 恶心, 头痛, 呕吐, 消化系统失调,
头晕, 虚弱, 混乱
附加说明
化学物质毒性作用登记: 无数据资料

模块12. 生态学资料
12.1 生态毒性
无数据资料
12.2 持久性和降解性
无数据资料
12.3 潜在的生物累积性
无数据资料
12.4 土壤中的迁移性
无数据资料
12.5 PBT 和 vPvB的结果评价
无数据资料
12.6 其它不良影响
无数据资料

模块13. 废弃处置
13.1 废物处理方法
产品
在装备有加力燃烧室和洗刷设备的化学焚烧炉内燃烧处理,特别在点燃的时候要注意,因为此物质是高度易燃
性物质 将剩余的和不可回收的溶液交给有许可证的公司处理。
受污染的容器和包装
按未用产品处置。

模块14. 运输信息
14.1 联合国危险货物编号
欧洲陆运危规: 1230国际海运危规: 1230国际空运危规: 1230
14.2 联合国运输名称
欧洲陆运危规: METHANOL, 溶液
国际海运危规: METHANOL, 溶液
国际空运危规: Methanol, 溶液
14.3 运输危险类别
欧洲陆运危规: 3 (6.1)国际海运危规: 3 (6.1)国际空运危规: 3 (6.1)
14.4 包裹组
欧洲陆运危规: II国际海运危规: II国际空运危规: II
14.5 环境危险
欧洲陆运危规: 否国际海运危规国际空运危规: 否
海洋污染物(是/否): 否
14.6 对使用者的特别提醒
无数据资料


模块 15 - 法规信息
N/A


模块16 - 其他信息
N/A

生态学数据:

对水是稍微危害的,若无政府许可,勿将材料排入周围环境

CHEMICAL IDENTIFICATION

RTECS NUMBER :
IH6125000
CHEMICAL NAME :
Digoxin
CAS REGISTRY NUMBER :
20830-75-5
BEILSTEIN REFERENCE NO. :
0077011
LAST UPDATED :
199701
DATA ITEMS CITED :
51
MOLECULAR FORMULA :
C41-H64-O14
MOLECULAR WEIGHT :
781.05

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
500 ug/kg
TOXIC EFFECTS :
Cardiac - EKG changes not diagnostic of specified effects Cardiac - pulse rate increase, without fall in BP Gastrointestinal - nausea or vomiting
REFERENCE :
CTOXAO Clinical Toxicology. (New York, NY) V.1-18, 1968-81. For publisher information, see JTCTDW. Volume(issue)/page/year: 15,437,1979
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
165 ug/kg/33D-I
TOXIC EFFECTS :
Behavioral - general anesthetic Behavioral - muscle contraction or spasticity
REFERENCE :
BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 296,1262,1988
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
100 ug/kg
TOXIC EFFECTS :
Behavioral - anorexia (human) Cardiac - arrhythmias (including changes in conduction) Gastrointestinal - nausea or vomiting
REFERENCE :
NZMJAX New Zealand Medical Journal. (New Zealand Medical Assoc., P.O. Box 156, Wellington, New Zealand) V.1- 1900- Volume(issue)/page/year: 84,443,1976
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
333 ug/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - visual field changes Cardiac - pulse rate
REFERENCE :
BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 287,392,1983
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - child
DOSE/DURATION :
127 ug/kg
TOXIC EFFECTS :
Cardiac - pulse rate
REFERENCE :
AFPYAE American Family Physician. (American Academy of Family Physicians, 1740 W. 92nd St., Kansas City, MO 64114) V.2-17, 1962-69; New series: V.2- 1970- Volume(issue)/page/year: 34(1),137,1986
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
75 ug/kg
TOXIC EFFECTS :
Cardiac - EKG changes not diagnostic of specified effects Cardiac - pulse rate increase, without fall in BP
REFERENCE :
AJEMEN American Journal of Emergency Medicine. (WB Saunders, Philadelphia, PA) V.1- 1983- Volume(issue)/page/year: 6,465,1988
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - child
DOSE/DURATION :
54 ug/kg
TOXIC EFFECTS :
Cardiac - pulse rate Nutritional and Gross Metabolic - changes in potassium
REFERENCE :
AJEMEN American Journal of Emergency Medicine. (WB Saunders, Philadelphia, PA) V.1- 1983- Volume(issue)/page/year: 4,364,1986
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Human - infant
DOSE/DURATION :
200 ug/kg
TOXIC EFFECTS :
Cardiac - pulse rate
REFERENCE :
PEDIAU Pediatrics. (American Academy of Pediatrics, P.O. Box 1034, Evanston, IL 60204) V.1- 1948- Volume(issue)/page/year: 77,848,1986
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Human - infant
DOSE/DURATION :
50 ug/kg
TOXIC EFFECTS :
Cardiac - pulse rate
REFERENCE :
AFPYAE American Family Physician. (American Academy of Family Physicians, 1740 W. 92nd St., Kansas City, MO 64114) V.2-17, 1962-69; New series: V.2- 1970- Volume(issue)/page/year: 34(1),137,1986
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
13 ug/kg/4D-I
TOXIC EFFECTS :
Behavioral - changes in psychophysiological tests Vascular - other changes Lungs, Thorax, or Respiration - dyspnea
REFERENCE :
AHJOA2 American Heart Journal. (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63146) V.1- 1925- Volume(issue)/page/year: 106,419,1983
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
28270 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 164,47,1966
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
4 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
JDGRAX Journal of Drug Research. (National Organization for Drug Research and Control, POB 29, Cairo, Egypt) V.2- 1969- Volume(issue)/page/year: 17,247,1987
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
8900 ng/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
RPTOAN Russian Pharmacology and Toxicology (English Translation). Translation of FATOAO. (Euromed Pub., 33, Woodlands Rd., Surbiton, Surrey, UK) V.30- 1967- Volume(issue)/page/year: 53,171,1990
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
25 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 155,165,1965
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Rectal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
5 mg/kg
TOXIC EFFECTS :
Cardiac - pulse rate
REFERENCE :
PLMEAA Planta Medica. (Georg Thieme Verlag, Postfach 732, D-7000 Stuttgart 1, Fed. Rep. Ger.) V.1- 1953- Volume(issue)/page/year: 25,88,1974
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
17780 ug/kg
TOXIC EFFECTS :
Brain and Coverings - recordings from specific areas of CNS Behavioral - convulsions or effect on seizure threshold Cardiac - other changes
REFERENCE :
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 153,436,1965
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
3964 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
CHTHBK Chemotherapy (Basel). (S. Karger Pub., Inc., 79 Fifth Ave., New York, NY 10003) V.13- 1968- Volume(issue)/page/year: 16,371,1971
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
8150 ng/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
RPTOAN Russian Pharmacology and Toxicology (English Translation). Translation of FATOAO. (Euromed Pub., 33, Woodlands Rd., Surbiton, Surrey, UK) V.30- 1967- Volume(issue)/page/year: 53,171,1990
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
7670 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
PLRCAT Pharmacological Research Communications. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1969- Volume(issue)/page/year: 6,417,1974
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intracerebral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
124 ug/kg
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold
REFERENCE :
PLRCAT Pharmacological Research Communications. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1969- Volume(issue)/page/year: 6,417,1974
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Parenteral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
2947 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
SIHSD8 Shang-hai I Hsueh. (China International Book Trading Corp., POB 2820, Beijing, Peop. Rep. China) V.1- 1978(?)- Volume(issue)/page/year: 4(2),32,1981
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
300 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
CRSBAW Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales. (SPPIF, B.P.22, F-41353 Vineuil, France) V.1- 1849- Volume(issue)/page/year: 109,279,1932
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
200 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
CRSBAW Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales. (SPPIF, B.P.22, F-41353 Vineuil, France) V.1- 1849- Volume(issue)/page/year: 109,279,1932
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - cat
DOSE/DURATION :
200 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 159,1,1966
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - cat
DOSE/DURATION :
159 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 19,657,1969
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Parenteral
SPECIES OBSERVED :
Mammal - cat
DOSE/DURATION :
1470 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
APPHAX Acta Poloniae Pharmaceutica. For English translation, see APPFAR. (Ars Polona, POB 1001, 00-680 Warsaw 1, Poland) V.1- 1937- Volume(issue)/page/year: 34,431,1977
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intraduodenal
SPECIES OBSERVED :
Mammal - cat
DOSE/DURATION :
441 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 20,1765,1970
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
3560 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,316,1982
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - pig
DOSE/DURATION :
230 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 20,229,1970
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intraduodenal
SPECIES OBSERVED :
Mammal - pig
DOSE/DURATION :
1580 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 20,229,1970
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - guinea pig
DOSE/DURATION :
3500 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 159,1,1966
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - guinea pig
DOSE/DURATION :
800 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 7,373,1973
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - guinea pig
DOSE/DURATION :
600 ug/kg
TOXIC EFFECTS :
Cardiac - arrhythmias (including changes in conduction)
REFERENCE :
JPPMAB Journal of Pharmacy and Pharmacology. (Pharmaceutical Soc. of Great Britain, 1 Lambeth High St., London SEI 7JN, UK) V.1- 1949- Volume(issue)/page/year: 35,580,1983
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - guinea pig
DOSE/DURATION :
468 ug/kg
TOXIC EFFECTS :
Brain and Coverings - recordings from specific areas of CNS Behavioral - convulsions or effect on seizure threshold Cardiac - other changes
REFERENCE :
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 153,436,1965
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Rodent - guinea pig
DOSE/DURATION :
630 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,316,1982
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraduodenal
SPECIES OBSERVED :
Rodent - guinea pig
DOSE/DURATION :
3200 ug/kg
TOXIC EFFECTS :
Cardiac - cardiomyopathy including infarction Cardiac - arrhythmias (including changes in conduction)
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 21,225,1971
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Bird - pigeon
DOSE/DURATION :
337 ug/kg
TOXIC EFFECTS :
Cardiac - arrhythmias (including changes in conduction) Cardiac - change in rate Gastrointestinal - nausea or vomiting
REFERENCE :
AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 126,412,1960
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Parenteral
SPECIES OBSERVED :
Bird - pigeon
DOSE/DURATION :
450 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
CPBTAL Chemical and Pharmaceutical Bulletin. (Japan Pub. Trading Co., USA, 1255 Howard St., San Francisco, CA 94103) V.6- 1958- Volume(issue)/page/year: 11,613,1963
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Amphibian - frog
DOSE/DURATION :
2240 ng/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
RPTOAN Russian Pharmacology and Toxicology (English Translation). Translation of FATOAO. (Euromed Pub., 33, Woodlands Rd., Surbiton, Surrey, UK) V.30- 1967- Volume(issue)/page/year: 53,171,1990
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Parenteral
SPECIES OBSERVED :
Amphibian - frog
DOSE/DURATION :
1 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
CPBTAL Chemical and Pharmaceutical Bulletin. (Japan Pub. Trading Co., USA, 1255 Howard St., San Francisco, CA 94103) V.6- 1958- Volume(issue)/page/year: 11,613,1963 ** OTHER MULTIPLE DOSE TOXICITY DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
462 ug/kg/30D-I
TOXIC EFFECTS :
Blood - other changes Nutritional and Gross Metabolic - changes in chlorine Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases
REFERENCE :
ARTODN Archives of Toxicology. (Springer-Verlag, Heidelberger Pl. 3, D-1000 Berlin 33, Fed. Rep. Ger.) V.32- 1974- Volume(issue)/page/year: 51,273,1982 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
810 ug/kg
SEX/DURATION :
female 1-18 week(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - blood and lymphatic systems (including spleen and marrow)
REFERENCE :
AJOGAH American Journal of Obstetrics and Gynecology. (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63146) V.1- 1920- Volume(issue)/page/year: 121,1100,1975 *** REVIEWS *** TOXICOLOGY REVIEW PHJOAV Pharmaceutical Journal. (Pharmaceutical Soc. of Great Britain, 1 Lambeth High St., London, SE1 7JN, UK) V.131- 1933- Volume(issue)/page/year: 213,159,1974 TOXICOLOGY REVIEW 85ELDJ "Die Herzwirksamen Glykoside," Baumgarten, G., and W. Forster, Leipzig, Ger. Dem. Rep., VEB Georg Thieme, 1963 Volume(issue)/page/year: -,190,1963 TOXICOLOGY REVIEW 85ELDJ "Die Herzwirksamen Glykoside," Baumgarten, G., and W. Forster, Leipzig, Ger. Dem. Rep., VEB Georg Thieme, 1963 Volume(issue)/page/year: -,54,1963 TOXICOLOGY REVIEW ASXBA8 Archives of Sexual Behavior. (Plenum Pub. Corp., 233 Spring St., New York, NY 10013) V.1- 1971- Volume(issue)/page/year: 9,343,1980 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 84688 No. of Facilities: 110 (estimated) No. of Industries: 2 No. of Occupations: 7 No. of Employees: 2855 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X9128 No. of Facilities: 171 (estimated) No. of Industries: 1 No. of Occupations: 7 No. of Employees: 1925 (estimated) No. of Female Employees: 1628 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 84688 No. of Facilities: 848 (estimated) No. of Industries: 4 No. of Occupations: 12 No. of Employees: 21318 (estimated) No. of Female Employees: 16552 (estimated)

符号 GHS02 GHS06 GHS08
GHS02, GHS06, GHS08
信号词 Danger
危害声明 H225-H301 + H311 + H331-H370
警示性声明 P210-P260-P280-P301 + P310-P311
个人防护装备 Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges
危害码 (欧洲) T:Toxic;
风险声明 (欧洲) R25
安全声明 (欧洲) S28-S45
危险品运输编码 UN 3462 6
WGK德国 3
RTECS号 IH6125000
包装等级 II
危险类别 6.1

~91%

20830-75-5结构式

20830-75-5

文献:Lepojevic, Zika; Pekic, Branislav Carbohydrate Research, 1995 , vol. 271, # 1 p. 119 - 124

~%

20830-75-5结构式

20830-75-5

文献:Pharmazie, , vol. 44, # 7 p. 508

~%

20830-75-5结构式

20830-75-5

文献:Helvetica Chimica Acta, , vol. 17, p. 592,601 35 <1952> 1318, 1321

~%

20830-75-5结构式

20830-75-5

文献:Journal of the American Pharmaceutical Association (1912-1977), , vol. 41, p. 146,150 Helvetica Chimica Acta, , vol. 17, p. 592,601 35 <1952> 1318, 1321

~%

20830-75-5结构式

20830-75-5

文献:Helvetica Chimica Acta, , vol. 17, p. 592,601 35 <1952> 1318, 1321

~%

20830-75-5结构式

20830-75-5

文献:Steroids, , vol. 38, # 1 p. 11 - 28

紫花洋地黄或毛花洋地黄干燥叶经发酵,再经乙醇、氯仿提取,最后用70%的乙醇溶液重结晶制得。